In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

Blood

Volumn 97, Issue 7, 2001, Pages 1999-2007

  Kano, Yasuhiko ^a   Akutsu, Miyuki ^b   Tsunoda, Saburo ^b   Mano, Hiroyuki ^b   Sato, Yuko ^b   Honma, Yoshio ^b   Furukawa, Yusuke ^b  

^a TOCHIGI CANCER CENTER   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ANTILEUKEMIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; METHOTREXATE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0035313251     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.7.1999     Document Type: Article

References (39)

1. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
2. Chronic myelogenous leukemia: A concise update
3. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
4. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias
5. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells
6. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
7. Tyrosine kinase activity and transformation potency of bcr/abl oncogene products
8. Chronic myelogenous leukemia: Biology and therapy
9. Acute lymphoblastic leukemia
10. Options for therapy in chronic myeloid leukaemia
11. Acycloguanosine and herbimycin A cooperatively inhibit proliferation and induce erythrodifferentiation of human myeloid leukemia K562 cells
12. Treatment of Philadelphia-chromosome-positive human leukemia in SCID mouse model with herbimycin A, bcr/abl tyrosine kinase activity inhibitor
13. In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells
14. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr/abl positive cells
15. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR/ABL-positive cells
16. The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR/ABL
17. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
18. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic meylogeous leukemia
19. Altered interferon-a responsiveness in K562 cells pretreated with abl-tyrosine kinase inhibitor CGP57148B
20. Efficacy of an abl tyrosine kinase inhibitor in conjunction with other anti-neoplastic agents against bcr-abl positive cells
21. Combination therapy of chronic myelogenous leukemia employing bcr/abl specific tyrosine kinase inhibition
22. The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia
23. In vitro effects of amsacrine in combination with other anti-cancer agents
24. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity
25. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture
26. Effects of CPT-11 in combination with other anti-cancer agents in culture
27. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines
28. What is synergy?
29. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia
30. Interferon alfa versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group
31. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: Low levels of minimal residual disease are associated with continuing remission
32. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea
33. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia
34. Homoharringtonine - Perspectives on an active new natural product
35. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia
36. In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide
37. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
38. Bcl-xL is phosphorylated in malignant cells following microtubule disruption
39. The tyrosine kinase inhibitor CGP57148 (STI571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X